Good morning! It's Jack and Paul here with the SCVR for Thursday.

Agenda -

Jack's section:

Mpac (LON:MPAC) - strong FY results with a positive order book performance boding well for future. The group is targeting both organic and acquisitive growth, it is executing well against its strategy, and there is plenty of room to grow market share. Worth a look.

Frontier Ip (LON:FIPP) - Frontier invests in spin outs with intellectual property, which it then helps to commercialise. Its prospects are tied to the quality of the investments it makes, but it’s a potentially interesting way to gain exposure to early-stage companies. Trading at around NAV, so scope for multiple expansion if the portfolio businesses develop.


Explanatory notes -

A quick reminder that we don’t recommend any stocks. We aim to review trading updates & results of the day and offer our opinions on them as possible candidates for further research if they interest you. Our opinions will sometimes turn out to be right, and sometimes wrong, because it's anybody's guess what direction market sentiment will take & nobody can predict the future with certainty. We are analysing the company fundamentals, not trying to predict market sentiment.

We stick to companies that have issued news on the day, with market caps up to about £700m. We avoid the smallest, and most speculative companies, and also avoid a few specialist sectors (e.g. natural resources, pharma/biotech).

A key assumption is that readers DYOR (do your own research), and make your own investment decisions. Reader comments are welcomed - please be civil, rational, and include the company name/ticker, otherwise people won't necessarily know what company you are referring to.


Jack's section

Mpac (LON:MPAC)

Share price: 509p (+8.99%)

Shares in issue: 19,894,138

Market cap: £101.3m

Full year results for the year to 31 December 2021

Mpac is a high-speed packaging and automation solutions provider. Previously more of a turnaround situation, the company is now firmly back on track with good operating momentum and further growth on the agenda.

Strong performance in FY21 with results exceeding market expectations and FY22 has started on track
  • Order intake up from £83.9m to £117.9m, and closing order book up from £55.5m to £78.4m,
  • Revenue +13% to £94.3m,
  • Underlying operating margin up from 7.8% to 9.3%,
  • Underlying earnings per share up from 31.4p to 39.7p,
  • Statutory profit before tax…

Unlock the rest of this article with a 14 day trial

Already have an account?
Login here